TWI384998B - 抗-ＴＧＦ-β受體II抗體 - Google Patents
抗-ＴＧＦ-β受體II抗體 Download PDFInfo
- Publication number
- TWI384998B TWI384998B TW098135300A TW98135300A TWI384998B TW I384998 B TWI384998 B TW I384998B TW 098135300 A TW098135300 A TW 098135300A TW 98135300 A TW98135300 A TW 98135300A TW I384998 B TWI384998 B TW I384998B
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- tgfβrii
- seq
- human
- sequence
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 claims description 79
- 230000027455 binding Effects 0.000 claims description 55
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 27
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 13
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 13
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims description 9
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 claims description 8
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000026731 phosphorylation Effects 0.000 claims description 8
- 238000006366 phosphorylation reaction Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000012286 ELISA Assay Methods 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000057208 Smad2 Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 70
- 206010028980 Neoplasm Diseases 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 29
- 108010009583 Transforming Growth Factors Proteins 0.000 description 27
- 102000009618 Transforming Growth Factors Human genes 0.000 description 27
- 238000000034 method Methods 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 230000000903 blocking effect Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 210000000066 myeloid cell Anatomy 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 7
- 102100022338 Integrin alpha-M Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000003289 regulatory T cell Anatomy 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000009134 cell regulation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101000764900 Arabidopsis thaliana Tryptophan synthase alpha chain Proteins 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101100206411 Mus musculus Tgfb2 gene Proteins 0.000 description 1
- 101500025613 Mus musculus Transforming growth factor beta-1 Proteins 0.000 description 1
- 101500026553 Mus musculus Transforming growth factor beta-3 Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 101000612210 Zea mays Indole-3-glycerol phosphate lyase, chloroplastic Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009066 down-regulation mechanism Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- -1 luciferin isothiocyanate Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19869708P | 2008-11-07 | 2008-11-07 | |
| US17036909P | 2009-04-17 | 2009-04-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201026326A TW201026326A (en) | 2010-07-16 |
| TWI384998B true TWI384998B (zh) | 2013-02-11 |
Family
ID=41508691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098135300A TWI384998B (zh) | 2008-11-07 | 2009-10-19 | 抗-ＴＧＦ-β受體II抗體 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8147834B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2356152A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5667067B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101283856B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102209727B (cg-RX-API-DMAC7.html) |
| AR (1) | AR073909A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009311375B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0921263A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2742961C (cg-RX-API-DMAC7.html) |
| EA (1) | EA025169B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL211842A (cg-RX-API-DMAC7.html) |
| JO (1) | JO3096B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011004871A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ591943A (cg-RX-API-DMAC7.html) |
| PA (1) | PA8846101A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201401280TA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI384998B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010053814A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201103178B (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012093125A1 (en) * | 2011-01-06 | 2012-07-12 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| EP4653013A2 (en) | 2014-10-31 | 2025-11-26 | The Trustees of the University of Pennsylvania | Methods and compositions for modified t cells |
| ES2947589T3 (es) | 2015-01-31 | 2023-08-11 | Univ Pennsylvania | Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| DK3365368T3 (da) | 2016-03-11 | 2023-06-26 | Scholar Rock Inc | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf |
| WO2017201527A2 (en) * | 2016-05-20 | 2017-11-23 | President And Fellows Of Harvard College | Gene therapy methods for age-related diseases and conditions |
| AR109770A1 (es) | 2016-10-18 | 2019-01-23 | Lilly Co Eli | ANTICUERPOS DEL RECEPTOR II DE TGF-b |
| CN117398457A (zh) * | 2017-01-06 | 2024-01-16 | 供石公司 | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 |
| CN106884005A (zh) * | 2017-01-19 | 2017-06-23 | 樊克兴 | 一种结直肠癌抗原特异性t细胞的制备方法 |
| US10899843B2 (en) | 2017-10-24 | 2021-01-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
| CN107973853B (zh) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| AU2020412201A1 (en) * | 2019-12-24 | 2022-07-14 | Merus N.V. | TGF-beta-RII binding proteins |
| KR102314157B1 (ko) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법 |
| KR20250005109A (ko) * | 2022-04-15 | 2025-01-09 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-cd40 항체 및 이의 용도 |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1245676A1 (en) * | 1999-11-18 | 2002-10-02 | Japan Tobacco Inc. | Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof |
| JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| CA2122491A1 (en) | 1991-10-31 | 1993-05-13 | Herbert Y. Lin | Tgf-.beta. type receptor cdnas and uses therefor |
| JPWO2007088651A1 (ja) | 2006-02-01 | 2009-06-25 | 国立大学法人 東京大学 | ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用 |
-
2009
- 2009-10-18 JO JOP/2009/0382A patent/JO3096B1/ar active
- 2009-10-19 PA PA20098846101A patent/PA8846101A1/es unknown
- 2009-10-19 AR ARP090104017A patent/AR073909A1/es unknown
- 2009-10-19 TW TW098135300A patent/TWI384998B/zh not_active IP Right Cessation
- 2009-10-29 AU AU2009311375A patent/AU2009311375B2/en not_active Ceased
- 2009-10-29 JP JP2011534731A patent/JP5667067B2/ja not_active Expired - Fee Related
- 2009-10-29 EP EP09745224A patent/EP2356152A1/en not_active Withdrawn
- 2009-10-29 KR KR1020117010399A patent/KR101283856B1/ko not_active Expired - Fee Related
- 2009-10-29 WO PCT/US2009/062450 patent/WO2010053814A1/en not_active Ceased
- 2009-10-29 MX MX2011004871A patent/MX2011004871A/es active IP Right Grant
- 2009-10-29 EA EA201170659A patent/EA025169B1/ru not_active IP Right Cessation
- 2009-10-29 BR BRPI0921263-9A patent/BRPI0921263A2/pt not_active IP Right Cessation
- 2009-10-29 CN CN200980144391.1A patent/CN102209727B/zh not_active Expired - Fee Related
- 2009-10-29 SG SG10201401280TA patent/SG10201401280TA/en unknown
- 2009-10-29 CA CA2742961A patent/CA2742961C/en not_active Expired - Fee Related
- 2009-10-29 US US12/608,034 patent/US8147834B2/en not_active Expired - Fee Related
- 2009-10-29 NZ NZ591943A patent/NZ591943A/xx not_active IP Right Cessation
-
2011
- 2011-03-21 IL IL211842A patent/IL211842A/en not_active IP Right Cessation
- 2011-04-29 ZA ZA2011/03178A patent/ZA201103178B/en unknown
-
2012
- 2012-02-20 US US13/400,308 patent/US20120177666A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1245676A1 (en) * | 1999-11-18 | 2002-10-02 | Japan Tobacco Inc. | Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof |
| JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体 |
Non-Patent Citations (2)
| Title |
|---|
| Hemmie R Hoogenboom, Selecting and screening recombinant antibody libraries, Nature Biotechnology, 2005, Vol. 23, pages 1105-1116 * |
| Teicher BA, Transforming growth factor-beta in in vivo resistance, Cancer Chemother Pharmacol, 1996, Vol.37, pages 601-9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201401280TA (en) | 2014-05-29 |
| BRPI0921263A2 (pt) | 2015-08-04 |
| CA2742961C (en) | 2016-08-30 |
| KR101283856B1 (ko) | 2013-07-15 |
| AU2009311375A1 (en) | 2010-05-14 |
| KR20110067155A (ko) | 2011-06-21 |
| EP2356152A1 (en) | 2011-08-17 |
| JO3096B1 (ar) | 2017-03-15 |
| JP2012508170A (ja) | 2012-04-05 |
| EA025169B1 (ru) | 2016-11-30 |
| NZ591943A (en) | 2012-11-30 |
| ZA201103178B (en) | 2012-10-31 |
| CA2742961A1 (en) | 2010-05-14 |
| MX2011004871A (es) | 2011-07-13 |
| AR073909A1 (es) | 2010-12-09 |
| US8147834B2 (en) | 2012-04-03 |
| US20120177666A1 (en) | 2012-07-12 |
| US20100119516A1 (en) | 2010-05-13 |
| WO2010053814A1 (en) | 2010-05-14 |
| CN102209727B (zh) | 2014-07-30 |
| AU2009311375B2 (en) | 2014-07-31 |
| CN102209727A (zh) | 2011-10-05 |
| IL211842A (en) | 2016-09-29 |
| JP5667067B2 (ja) | 2015-02-12 |
| PA8846101A1 (es) | 2010-06-28 |
| IL211842A0 (en) | 2011-06-30 |
| EA201170659A1 (ru) | 2011-10-31 |
| TW201026326A (en) | 2010-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI384998B (zh) | 抗-ＴＧＦ-β受體II抗體 | |
| JP2012508170A5 (cg-RX-API-DMAC7.html) | ||
| JP5583591B2 (ja) | Ｗｉｓｅ結合抗体及びエピトープ | |
| KR101523788B1 (ko) | 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조 | |
| JP2021508676A (ja) | 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用 | |
| EP2925778B1 (en) | Anti-vegf antibodies and their uses | |
| CN105829345B (zh) | 结合egfr和met的多功能抗体 | |
| JP6910963B2 (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| US11008387B2 (en) | Antibody inhibiting binding of VEGF to NRP1 | |
| JP6231632B2 (ja) | Ａｎｇ２抗体 | |
| JP2024529119A (ja) | 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用 | |
| US20240383974A1 (en) | Bispecific antibody and application thereof | |
| US12319746B2 (en) | Bispecific antibody specifically binding to GPNMB and CD3, and use thereof | |
| CN118791607B (zh) | 双特异性抗体及其应用 | |
| JP7643727B2 (ja) | 抗－ｆｇｆ１９抗体 | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| CN118791606A (zh) | 双特异性抗体及其应用 | |
| HK1167325A1 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| HK1167325B (en) | Antibodies against vascular endothelial growth factor receptor-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |